vs

Side-by-side financial comparison of GRAFTECH INTERNATIONAL LTD (EAF) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.

GRAFTECH INTERNATIONAL LTD is the larger business by last-quarter revenue ($125.1M vs $85.1M, roughly 1.5× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -34.6%, a 57.4% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 11.9%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-27.1M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -4.6%).

GrafTech International Ltd. is a manufacturer of graphite electrodes and petroleum coke, which are essential for the production of electric arc furnace steel and other metals. Headquartered in Brooklyn Heights, Ohio, it has manufacturing facilities in Calais, France;Pamplona, Spain; Monterrey, Mexico; and St. Marys, Pennsylvania.

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

EAF vs FDMT — Head-to-Head

Bigger by revenue
EAF
EAF
1.5× larger
EAF
$125.1M
$85.1M
FDMT
Growing faster (revenue YoY)
FDMT
FDMT
+8508888.1% gap
FDMT
8508900.0%
11.9%
EAF
Higher net margin
FDMT
FDMT
57.4% more per $
FDMT
22.8%
-34.6%
EAF
More free cash flow
FDMT
FDMT
$55.6M more FCF
FDMT
$28.5M
$-27.1M
EAF
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-4.6%
EAF

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EAF
EAF
FDMT
FDMT
Revenue
$125.1M
$85.1M
Net Profit
$-43.3M
$19.4M
Gross Margin
-7.8%
Operating Margin
17.3%
Net Margin
-34.6%
22.8%
Revenue YoY
11.9%
8508900.0%
Net Profit YoY
-10.0%
139.1%
EPS (diluted)
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EAF
EAF
FDMT
FDMT
Q1 26
$125.1M
Q4 25
$116.5M
$85.1M
Q3 25
$144.0M
$90.0K
Q2 25
$131.8M
$15.0K
Q1 25
$111.8M
$14.0K
Q4 24
$134.2M
$1.0K
Q3 24
$130.7M
$3.0K
Q2 24
$137.3M
$5.0K
Net Profit
EAF
EAF
FDMT
FDMT
Q1 26
$-43.3M
Q4 25
$-65.1M
$19.4M
Q3 25
$-28.5M
$-56.9M
Q2 25
$-86.9M
$-54.7M
Q1 25
$-39.4M
$-48.0M
Q4 24
$-49.5M
Q3 24
$-36.1M
$-43.8M
Q2 24
$-14.8M
$-35.0M
Gross Margin
EAF
EAF
FDMT
FDMT
Q1 26
-7.8%
Q4 25
-20.9%
Q3 25
7.2%
Q2 25
0.0%
Q1 25
-1.5%
Q4 24
-7.8%
Q3 24
-9.2%
Q2 24
2.9%
Operating Margin
EAF
EAF
FDMT
FDMT
Q1 26
Q4 25
-33.6%
17.3%
Q3 25
-3.6%
-67983.3%
Q2 25
-11.0%
-396373.3%
Q1 25
-16.3%
-383007.1%
Q4 24
-18.6%
Q3 24
-20.1%
-1704400.0%
Q2 24
-2.0%
-849120.0%
Net Margin
EAF
EAF
FDMT
FDMT
Q1 26
-34.6%
Q4 25
-55.9%
22.8%
Q3 25
-19.8%
-63195.6%
Q2 25
-65.9%
-364386.7%
Q1 25
-35.2%
-342657.1%
Q4 24
-36.9%
Q3 24
-27.6%
-1461433.3%
Q2 24
-10.7%
-699060.0%
EPS (diluted)
EAF
EAF
FDMT
FDMT
Q1 26
Q4 25
$-6.86
$0.43
Q3 25
$-1.10
$-1.01
Q2 25
$-0.34
$-0.98
Q1 25
$-0.15
$-0.86
Q4 24
$-3.51
Q3 24
$-1.40
$-0.79
Q2 24
$-0.06
$-0.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EAF
EAF
FDMT
FDMT
Cash + ST InvestmentsLiquidity on hand
$120.2M
$402.7M
Total DebtLower is stronger
$1.1B
Stockholders' EquityBook value
$505.7M
Total Assets
$997.2M
$566.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EAF
EAF
FDMT
FDMT
Q1 26
$120.2M
Q4 25
$402.7M
Q3 25
$305.1M
Q2 25
$293.2M
Q1 25
$321.4M
Q4 24
$424.9M
Q3 24
$501.9M
Q2 24
$120.7M
$541.9M
Total Debt
EAF
EAF
FDMT
FDMT
Q1 26
$1.1B
Q4 25
$1.1B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
$929.5M
Q2 24
$928.2M
Stockholders' Equity
EAF
EAF
FDMT
FDMT
Q1 26
Q4 25
$-259.6M
$505.7M
Q3 25
$-194.4M
$369.0M
Q2 25
$-168.4M
$420.9M
Q1 25
$-105.3M
$469.7M
Q4 24
$-78.9M
$510.6M
Q3 24
$-9.0M
$552.9M
Q2 24
$16.2M
$588.3M
Total Assets
EAF
EAF
FDMT
FDMT
Q1 26
$997.2M
Q4 25
$1.0B
$566.7M
Q3 25
$1.1B
$424.0M
Q2 25
$1.1B
$473.6M
Q1 25
$1.2B
$515.7M
Q4 24
$1.2B
$560.4M
Q3 24
$1.1B
$604.0M
Q2 24
$1.2B
$620.1M
Debt / Equity
EAF
EAF
FDMT
FDMT
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
57.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EAF
EAF
FDMT
FDMT
Operating Cash FlowLast quarter
$-14.9M
$28.6M
Free Cash FlowOCF − Capex
$-27.1M
$28.5M
FCF MarginFCF / Revenue
-21.6%
33.5%
Capex IntensityCapex / Revenue
9.7%
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-105.1M
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EAF
EAF
FDMT
FDMT
Q1 26
$-14.9M
Q4 25
$-20.9M
$28.6M
Q3 25
$24.7M
$-46.5M
Q2 25
$-53.2M
$-43.4M
Q1 25
$-32.2M
$-47.8M
Q4 24
$-26.4M
$-134.6M
Q3 24
$23.7M
$-29.4M
Q2 24
$-36.9M
$-30.2M
Free Cash Flow
EAF
EAF
FDMT
FDMT
Q1 26
$-27.1M
Q4 25
$-39.3M
$28.5M
Q3 25
$18.4M
$-46.6M
Q2 25
$-57.1M
$-43.4M
Q1 25
$-42.5M
$-48.4M
Q4 24
$-39.2M
$-138.4M
Q3 24
$19.7M
$-31.2M
Q2 24
$-43.8M
$-30.6M
FCF Margin
EAF
EAF
FDMT
FDMT
Q1 26
-21.6%
Q4 25
-33.7%
33.5%
Q3 25
12.8%
-51765.6%
Q2 25
-43.3%
-289620.0%
Q1 25
-38.0%
-345635.7%
Q4 24
-29.2%
-13837100.0%
Q3 24
15.1%
-1038966.7%
Q2 24
-31.9%
-611840.0%
Capex Intensity
EAF
EAF
FDMT
FDMT
Q1 26
9.7%
Q4 25
15.8%
0.1%
Q3 25
4.4%
101.1%
Q2 25
3.0%
440.0%
Q1 25
9.2%
4507.1%
Q4 24
9.5%
378600.0%
Q3 24
3.1%
59266.7%
Q2 24
5.1%
6980.0%
Cash Conversion
EAF
EAF
FDMT
FDMT
Q1 26
Q4 25
1.47×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons